Table 3.
Roles of insulin resistance-related indices in the trajectory of cardiometabolic multimorbidity progression among participants with MASLD
| Exposures | HRs (95% CIs) | |||||
|---|---|---|---|---|---|---|
| Transition A (Healthy—> T2D) |
Transition B (Healthy—> Stroke) |
Transition C (Healthy—> CHD) |
Transition D (T2D—> CMM) |
Transition E (Stroke—> CMM) |
Transition F (CHD—> CMM) |
|
|
No. of cases/ total population |
12,371/109,604 | 4,083/109,604 | 10,988/109,604 | 1,988/12,371 | 896/4,083 | 2,060/10,988 |
| Proportions | 11.3% | 3.7% | 10.0% | 16.1% | 21.9% | 18.7% |
| TyG | 1.60 (1.57–1.62)* | 0.97 (0.94–1.00) | 1.10 (1.08–1.12)* | 1.04 (1.00–1.08)* | 1.20 (1.12–1.28)* | 1.33 (1.27–1.39)* |
| TyG-BMI | 1.67 (1.65–1.70)* | 1.01 (0.97–1.04) | 1.05 (1.03–1.08)* | 1.10 (1.06–1.14)* | 1.27 (1.19–1.35)* | 1.42 (1.37–1.47)* |
| TyG-WC | 1.74 (1.72–1.77)* | 1.05 (1.01–1.08)* | 1.16 (1.14–1.18)* | 1.11 (1.08–1.16)* | 1.31 (1.23–1.39)* | 1.41 (1.36–1.47)* |
| TyG-WHtR | 1.81 (1.79–1.84)* | 1.08 (1.04–1.11)* | 1.10 (1.08–1.12)* | 1.11 (1.07–1.15)* | 1.31 (1.23–1.39)* | 1.47 (1.42–1.53)* |
| TyG-BRI | 1.62 (1.60–1.64)* | 1.09 (1.06–1.13)* | 1.07 (1.05–1.09)* | 1.10 (1.06–1.14)* | 1.26 (1.18–1.33)* | 1.37 (1.32–1.42)* |
| TyG-ABSI | 1.48 (1.45–1.51)* | 1.11 (1.08–1.15)* | 1.20 (1.18–1.23)* | 1.09 (1.04–1.13)* | 1.21 (1.13–1.30)* | 1.26 (1.20–1.32)* |
| TyG-VAI | 1.27 (1.25–1.28)* | 0.98 (0.95–1.01) | 1.09 (1.07–1.11)* | 1.04 (1.00–1.07)* | 1.09 (1.02–1.16)* | 1.16 (1.12–1.20)* |
| TyG-WWI | 1.71 (1.68–1.74)* | 1.10 (1.07–1.14)* | 1.13 (1.11–1.16)* | 1.08 (1.04–1.12)* | 1.25 (1.16–1.33)* | 1.39 (1.33–1.45)* |
| TG/HDL-C ratio | 1.22 (1.20–1.23)* | 0.97 (0.94–1.00) | 1.13 (1.11–1.15)* | 1.05 (1.02–1.09)* | 1.07 (1.00–1.15)* | 1.12 (1.08–1.16)* |
*P < 0.05. HRs (95% CIs) are reported per one standard deviation increment in each index. Models were adjusted for age, sex, ethnicity, educational levels, Townsend deprivation index, frequency of drinking, smoking status, physical activity, self-reported history of hypertension, self-reported history of cancer, use of lipid-lowering medication, use of antihypertensive medication, and family history of cardiometabolic disease. Baseline MASLD indicates participants with MASLD who were free of type 2 diabetes, stroke, and coronary heart disease at study entry. All transitions are illustrated in Fig. 2
HR, hazard ratio; CI, confidence interval; CMM, cardiometabolic multimorbidity; CHD, coronary heart disease; T2D, type 2 diabetes; MASLD, metabolic dysfunction-associated steatotic liver disease; TyG, triglyceride-glucose index; BMI, body mass index; WC, waist circumference; WHtR, waist-to-height ratio; BRI, body roundness index; ABSI, a body shape index; VAI, visceral adiposity index; WWI, weight-adjusted waist index; TG/HDL-C, triglyceride-to-high-density lipoprotein cholesterol ratio